文献速递MDS 与骨髓增殖性肿瘤

真性红细胞增多症的治疗与临床终点:寻求可获得的最佳真相版本

Treatment and clinical endpoints in polycythemia vera: seeking the best obtainable version of the truth.
PubMed 文献 · Blood · 2022-01-01

本文是一篇关于真性红细胞增多症(PV)治疗与临床终点的观点性综述,指出治疗规划需基于传统风险特征(年龄、既往血栓)的持续再评估,在低剂量阿司匹林和严格放血基础上决定是否需降细胞治疗。降细胞药物除羟基脲外,基于3期随机试验的芦可替尼和罗培干扰素α-2b已获监管批准。文章重点讨论短期终点(血细胞比容控制、症状负担/生活质量、脾大、JAK2 V617F等位基因负荷)与长期终点(血栓、骨髓纤维化转化、急性髓系白血病、生存)的证据获取挑战及数据缺口。

要点

  • PV治疗规划需持续再评估年龄和既往血栓等传统风险特征以决定是否降细胞。
  • 芦可替尼和罗培干扰素α-2b基于3期随机试验获监管批准,拓展了降细胞药物选择。
  • 血栓事件率低及长期终点使试验难以有足够把握度捕捉显著差异。

核心结论

  • 本文强调在PV新兴治疗格局中,短期终点证据较易获得,但血栓及长期终点因事件率低而难以通过试验充分把握,存在数据缺口和未决问题。

研究设计与样本

  • 本文为观点性综述(Perspective),围绕PV治疗与临床终点相关证据和挑战进行讨论。

主要发现

  • PV自然病史可长达数十年,治疗规划需基于年龄、既往血栓等传统风险特征的持续再评估。
  • 羟基脲在过去半个世纪是许多实践者的常规降细胞选择。
  • 基于3期随机试验,芦可替尼和罗培干扰素α-2b近期获监管批准,活性药物组合不断扩大。
  • 血细胞比容控制、症状负担/生活质量、脾大和JAK2 V617F等位基因负荷等短期终点的高水平证据在多数研究时间线内可获得。
  • 血栓事件率通常较低,骨髓纤维化转化、急性髓系白血病和生存等长期终点在多数情况下可能无法使试验有足够把握度捕捉显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Polycythemia vera (PV) is a Philadelphia chromosome-negative myeloproliferative neoplasm driven by the JAK2 V617F (or rarely exon 12) mutation. Its natural history can extend over a few decades, and therefore treatment planning is predicated on continual reassessment of traditional risk features (age, prior thrombosis) to evaluate the need for cytoreduction besides foundational therapy with low-dose aspirin and stringent phlebotomy. Shorter- and longer-term patient goals should be considered in light of several variables such as comorbid conditions (especially cardiovascular risk factors), disease symptoms, and the risk-benefit profile of available drugs. While hydroxyurea has been the pro forma choice of cytoreduction for many practitioners over the last half-century, the more recent regulatory approvals of ruxolitinib and ropeginterferon-alfa-2b, based on phase 3 randomized trials, highlight an expanding portfolio of active drugs. Obtaining high-level evidence for short-term clinical trial endpoints such as hematocrit control, symptom burden/quality of life, splenomegaly, and JAK2 V617F allele burden lies within the timeline of most studies. However, in many cases, it may not be possible to adequately power trials to capture significant differences in the typically low event rates of thrombosis as well as longer-horizon endpoints such as evolution to myelofibrosis and acute myeloid leukemia and survival. This Perspective highlights the challenges of addressing these data gaps and outstanding questions in the emerging treatment landscape of PV.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Gotlib J. Treatment and clinical endpoints in polycythemia vera: seeking the best obtainable version of the truth. Blood. 2022. PMID: 35271702. doi:10.1182/blood.2022015680

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。